Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA.tHIVconsv3
- Development stage
- Phase 2
- Lead developer
- University of Oxford
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA.tHIVconsv3 is an investigational therapeutic HIV vaccine candidate based on the Modified Vaccinia Ankara (MVA) viral vector platform. It encodes a conserved mosaic immunogen (tHIVconsv3), which is designed to induce robust and broad cytotoxic T lymphocyte (CTL) responses targeting highly conserved regions of the HIV-1 proteome. The goal is to overcome viral escape by focusing immune responses on parts of the virus that are less likely to mutate without compromising viral fitness. This vaccine is being developed primarily for use in people living with HIV, aiming to achieve better control of the virus during or after antiretroviral therapy interruption. It has been evaluated in combination with other vaccines such as ChAdOx1.tHIVconsv1 and tHIVconsv4 in sequential regimens, and has reached Phase 1/2 clinical trials[1][4][6]. The University of Oxford is leading its development.
- Other names
- MVA.HIVconsv
02
Targets
HIV-TCR (HIV-specific T-cell receptor)
Beyond the preview
Go deeper on MVA.tHIVconsv3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA.tHIVconsv3.